Andexanet Alfa for Rivaroxaban Reversal in Intracranial Hemorrhage

Introduction to Andexanet Alfa

The American College of Cardiology recommends administering andexanet alfa immediately for patients with presumed intracranial hemorrhage on rivaroxaban, as it is the only FDA-approved specific reversal agent for rivaroxaban and should be given without delay in life-threatening bleeding 1, 2
Andexanet alfa is the specific reversal agent for rivaroxaban, acting as a modified recombinant factor Xa that binds factor Xa inhibitors with high affinity, rapidly reversing anticoagulation within minutes, as recommended by the American College of Cardiology 3, 4

The 2020 ACC Expert Consensus Decision Pathway explicitly recommends andexanet alfa as first-line therapy for patients on rivaroxaban or apixaban presenting with major bleeding, including intracranial hemorrhage, according to the American College of Cardiology 1, 2
Andexanet reduces anti-factor Xa activity by 92% for rivaroxaban, with effects occurring within 2-5 minutes of administration and sustained throughout the infusion period, as reported in Circulation 3

In the ANNEXA-4 trial, 79% of patients achieved effective hemostasis at 12 hours after andexanet administration for major bleeding events, as published in Circulation 3

A high-dose regimen is indicated for rivaroxaban reversal in emergent scenarios, consisting of an 800 mg IV bolus administered at 30 mg/min, followed by a 960 mg continuous infusion at 8 mg/min for up to 120 minutes, as recommended by the American College of Cardiology 1

The American College of Cardiology advises against delaying andexanet administration for laboratory confirmation of rivaroxaban levels in life-threatening bleeding situations like intracranial hemorrhage, although this guideline is also supported by Praxis Medical Insights 5
The reversal effect of andexanet alfa is transient, with anti-factor Xa activity returning toward baseline approximately 2 hours after completing the infusion, so definitive bleeding control measures must be implemented during this window, as reported in Circulation and Praxis Medical Insights 3, 5
Thrombotic events occurred in 18% of patients within 30 days in the ANNEXA-4 trial, highlighting the need for careful consideration of anticoagulation resumption timing once hemostasis is achieved, as published in Circulation 3

If andexanet alfa is not available, the American College of Cardiology recommends administering four-factor prothrombin complex concentrate (4F-PCC) at 50 units/kg (maximum 5000 units) or activated PCC, though these are less effective and not specifically studied for rivaroxaban reversal, as reported in the Journal of the American College of Cardiology and Praxis Medical Insights 1, 4, 5

The American College of Cardiology suggests considering activated charcoal 50g if rivaroxaban ingestion occurred within 2-4 hours, though this is unlikely given the emergent presentation, as recommended in the Journal of the American College of Cardiology 1, 2
Neurosurgical consultation should occur simultaneously with reversal agent administration for potential surgical intervention, as advised by Praxis Medical Insights 5